Form 4: Kymera Therapeutics Director, John Maraganore, Acquires 16,000 Stock Options
SEC Form 4 Filing
Director John Maraganore acquired 16,000 stock options in Kymera Therapeutics, Inc. on June 18, 2024.
Summary
- On June 18, 2024, John Maraganore, a director of Kymera Therapeutics, Inc., acquired 16,000 stock options.
- The exercise price of these options is $31.20.
- The options vest fully on the earlier of June 18, 2025, or the date of the next annual meeting of the Issuer's stockholders.
- The options expire on June 17, 2034.
- Following the transaction, Maraganore directly owns 16,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date of transaction: John Maraganore acquired 16,000 stock options. |
| 06/18/2025 | Earliest vesting date for the stock options. |
| 06/17/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.